阿尔茨海默氏症模型芯片与微质BV2细胞
Ehsan Yazdanpanah Moghadam1,2, Nahum Sonenberg2, Muthukumaran Packirisamy3
1Optical-Bio Microsystems Laboratory, Micro-Nano-Bio Integration Center, Department of Mechanical and Industrial Engineering, Concordia University, Montreal, H3G 1M8, Canada.
Microsystems & nanoengineering
|July 7, 2025
概括
粉样β oligomers (AβO) 通过改变微质细胞粘附,影响阿尔茨海默病 (AD). 这项研究使用了微流体装置来量化AβO对细胞基质粘附的影响,揭示了随着AβO度和化时间的增加而减少的粘附.
科学领域:
- 神经科学是一个神经科学.
- 生物技术是生物技术.
- 细胞生物学 细胞生物学
背景情况:
- 粉样β oligomers (AβO) 是阿尔茨海默氏症 (AD) 病变发生的关键参与者.
- 微质细胞,大脑的免疫细胞,与AβO相互作用,影响它们的机械生物特性.
- 改变的微质粘附强度是AD进展的潜在生物标志物.
研究的目的:
- 开发和使用无标签的微流体装置作为检测AD疾病进展的体外模型.
- 量化评估不同AβO度对微质细胞基质粘附强度的影响.
- 了解AβO暴露后微质中的机械生物学变化.
主要方法:
- 用一个单通道的微流体装置作为细胞粘附试验.
- 微体BV2细胞暴露于不同的AβO度 (1μM,2.5μM,5μM).
- 使用显微镜实时量化细胞基质粘附在受控流量剪切应力 (3Pa和7.5Pa) 下.
主要成果:
- 微流体装置成功地发现了AβO度的上升.
- 增加AβO的潜伏时间导致细胞基质粘附强度降低.
- 较高的AβO度进一步削弱了微质对基质的附着性.
结论:
- 在微流体系统中量化微质细胞基质粘附是建模AD的可行方法.
- 微质中的机械生物学变化,特别是粘附强度,是AβO暴露和AD进展的敏感指标.
- 这种方法可以在体外AD模型中更深入地了解微质-AβO相互作用.
相关概念视频
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42


